论文部分内容阅读
体内和体外研究发现生长抑素合成物octreotide和黄体素释放激素(LHRH)合成物goserelin可减慢人胰腺癌的生长速度。迄今为止,用octreotide和/或goserelin治疗人胰腺外分泌性癌肿的各种试验尚无令人满意的治疗结果。本试验研究的目的是联合应用octreotide和goserelin作为晚期外分泌性胰腺癌病人的姑息性治疗,并对该方案的抗肿瘤效应和毒性进行评价。
In vivo and in vitro studies have found that the somatostatin composition octreotide and lutein releasing hormone (LHRH) composition goserelin can slow the growth rate of human pancreatic cancer. To date, there have been no satisfactory treatment outcomes for various trials of octreotide and/or goserelin in the treatment of human pancreatic exocrine cancers. The purpose of this trial study was to combine octreotide and goserelin as palliative treatments for patients with advanced exocrine pancreatic cancer and to evaluate the anti-tumor effect and toxicity of this regimen.